Suggestions
Paul Loeffen
Chief Executive Officer at Lightcast Discovery
Paul Loeffen is the Chief Executive Officer at Lightcast Discovery, a company that develops programmable microfluidic tools for single cell analysis.12 He has held this position since December 2020.2
Career History
Prior to his current role, Loeffen had an extensive career in the scientific and technology sectors:
- Vice President and General Manager at Agilent Technologies (2019-2020), leading the Molecular Spectroscopy business2
- Director of Raman Spectroscopy at Agilent Technologies (2017-2019)2
- CEO of Cobalt Light Systems Limited (2009-2017), which was acquired by Agilent in 20172
- CEO of Oxford Diffraction Ltd (2001-2009)2
- Marketing Manager at Oxford Instruments (1997-2001)2
Earlier in his career, Loeffen worked as a scientist at the European Synchrotron Radiation Facility (ESRF) and as a research student at the European Molecular Biology Laboratory and CERN.2
Education
Paul Loeffen has a strong academic background in physics:
- PhD in Physics from the University of Warwick (1989-1993)2
- MBA from Oxford Brookes University (1999-2001)2
- BSc in Physics from the University of Warwick (1985-1989)2
Skills and Languages
Loeffen has professional working proficiency in French and limited working proficiency in German.2
Recent Developments
Under Loeffen's leadership, Lightcast Discovery has made significant progress:
- In July 2024, the company announced the formation of a Scientific Advisory Board3
- In August 2023, Lightcast secured $49 million in Series B funding4
Paul Loeffen's extensive experience in scientific instrumentation and business leadership positions him well to guide Lightcast Discovery in its mission to advance single-cell analysis technology.
Highlights
Great to be at the Illumina Ventures annual meeting in beautiful San Francisco and have the opportunity to speak about deep functional profiling with the Lightcast single cell platform which we believe will be a game-changer in drug development and immunotherapy. I also enjoyed the panel discussion on scaling high quality data generation. Exciting times for Lightcast!
#singlecell #immunotherapy
The power of single-cell analysis to uncover the complexities of biology has become increasingly evident, but much of the work still focuses on the transcriptome as the primary readout. The next stage is to enable functional single-cell analysis at a comparable scale and with increased precision and control. With Lightcast’s new £38 million (c. $49 million) funding round, we will drive commercialization of our platform to meet the critical need of unifying diverse functional assays into a streamlined workflow to accelerate drug development. #singlecell #functionalanalysis #drugdevelopment #translationalresearch
